BRCA2 deficiency causes genome instability and breast and ovarian cancer predisposition, but also paradoxically promotes cell lethality. The nature of the acute, detrimental consequences of BRCA2 loss is not fully understood. We recently generated BRCA2 conditional models from a non-transformed human mammary cell line, through allele-specific gene targeting using CRISPR-Cas9, which we now describe. With these models, we discovered that BRCA2 deficiency triggers a DNA under replication-53BP1 nuclear body formation-G1 arrest axis due to homologous recombination defects. In this Extra-view, we extend these findings to show that 53BP1 nuclear bodies are spatially linked with downstream p53 activation. Replication stress that leads to common fragile site expression to induce 53BP1 nuclear body formation is aggravated by the loss of BRCA2. Additionally, replication stress that does not selectively lead to common fragile site expression is also able to induce 53BP1 nuclear body formation in BRCA2-deficient cells, indicating lesions form more globally throughout the genome.
Introduction
BRCA2, along with BRCA1, was identified as tumor suppressor genes of hereditary breast and ovarian cancers more than two decades ago [1, 2, 3] . With the widespread sequencing of tumor genomes, somatic as well as germline BRCA2 mutations have been associated with both the onset and advanced stages of several tumor types [4, 5, 6] . Both BRCA1 and BRCA2 are critical in preventing genome instability, a hallmark of cancer. We now know that they play roles in at least two processes essential for genome integrity maintenance: homologous recombination (HR) to repair lethal DNA lesions, including double-strand breaks, and replication fork protection (FP) to prevent nascent strand degradation at stalled replication forks [7] .
While sharing many key players, including BRCA2, HR and FP are both genetically and functionally separable processes [8] . Our mechanistic understanding of FP has recently advanced by the discovery of the role of replication fork reversal, where a fork regresses to form a fourway "chicken foot"-like structure [9] . In a FP-deficient background, reversed forks serve as the substrate for subsequent nascent strand degradation by nucleases [10, 11, 12, 13 ]. An HR defect in BRCA1/2-mutated cancers was initially leveraged to develop synthetic-lethality-based therapeutic strategies, while subsequent restoration of HR and/or possibly FP in tumors confers resistance [7] . The relative contribution of HR, FP, and now fork reversal to genome integrity is complex and may be contingent upon the cellular context [8] .
Modeling BRCA2 deficiency in a non-transformed background may provide insight into the early events that initiate BRCA2-mutated breast cancer formation. To this end, we recently leveraged the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-Cas9 tools to generate two BRCA2 conditional models in MCF10A cells [14] , a non-transformed human mammary epithelial cell line [15] . In the process, we also developed a CRISPR-Cas9-based approach for allele-specific gene targeting at the BRCA2 locus.
With these BRCA2 conditional models, we demonstrated that BRCA2 deficiency leads to replication stress and DNA under replication that in turn causes abnormalities during mitosis and 53BP1 nuclear body formation in the subsequent G1 phase, accompanied by a p53-mediated G1 arrest and ultimately cell lethality [14] . In dissecting the relative contribution of the HR and FP pathways, we provided evidence that cell viability and replication stress suppression are mainly mediated by the HR function of BRCA2, but not FP, in these non-transformed human mammary epithelial cells [14] . Here, we further explore the consequences of BRCA2 deficiency, with a focus on 53BP1 nuclear bodies, in particular their possible upstream triggers and downstream link with p53 activation. The role of the fork reversal protein SMARCAL1 and its functional interaction with BRCA2 is also examined.
Results and discussion
Allele-specific editing of the BRCA2 locus While generating the two BRCA2 conditional models in MCF10A cells [14] , CRISPR-Cas9-facilitated gene targeting was employed to achieve the desired editing outcome. One of the BRCA2 conditional systems we described involved first targeting two loxP sites to flank exons 3 and 4 of one allele (fl); the remaining WT allele was targeted using a promoterless selectable marker inserted at the BRCA2 start codon (Hyg-targeted) (Fig. S1 ) [14] . However, the start codon resides in exon 2, which is present in both the fl and WT alleles. Therefore, one technical challenge we anticipated was to specifically target the WT allele with the Hyg-targeting vector, while leaving exon 2 of the fl allele intact (Fig. 1A) .
To this end, we developed a method to achieve allele-specific targeting, which we benchmarked in BRCA2 +/+ cells to demonstrate its generality. We first sequenced the BRCA2 exon 2 region and identified a single nucleotide polymorphism (SNP). The sgRNA was then designed specifically for the allele containing the G nucleotide SNP ("G allele") residing towards the 3' end of the sgRNA sequence (Fig. 1A) , i.e., the seed region of the sgRNA that is sensitive to mismatches [16, 17, 18] . The post-transfection clones showing Hyg resistance were screened by a PCR specific for the Hyg cassette correctly integrated at the BRCA2 locus (Fig. 1B) . To characterize the other allele in the positive clones, PCR was performed with a reverse primer specific to an untargeted BRCA2 allele. All clones tested exhibited a positive PCR product, indicating monoallelic gene targeting with the Hyg cassette (Fig. 1B) . Sequencing of these PCR products revealed a strong bias (95.2%, 19/20) towards the allele with the A nucleotide SNP ("A allele"), such that Hyg targeting predominantly occurred at the G allele (Fig. 1C, D) . Therefore, polymorphism of even a single nucleotide at the sgRNA site can strongly bias targeting towards one specific allele. We then applied this strategy to our BRCA2 fl/+ cells, in this case targeting the A allele with the Hyg cassette using an A allele-specific sgRNA, as the prior fl targeting turned out to occur to the G allele (Fig. S1 ).
Achieving allele discrimination provides advantages for a variety of applications. For example, selectively disrupting or correcting dominant disease-causing alleles has potential clinical value. Accomplishing allele discrimination can also benefit basic research, such as achieving allele-specific imaging or studying one particular allele of interest, e.g. the maternal vs. the paternal allele. While alleles can be effectively distinguished via CRISPR approaches in cases where a unique PAM is present in one allele [19, 20] , discrimination between alleles with single nucleotide mismatches within the sgRNA site is conceptually challenging given the promiscuity of sgRNA recognition [16, 17, 18] . In this regard, previous studies have shown promise in utilizing SNPs in the sgRNA target regions to achieve allele-specific mutagenesis [21, 22, 23, 24, 25] . Our results now extend allele-specific applications to HR-mediated gene targeting. Notably, allele selectivity can be further improved with a truncated sgRNA design [25] , since it displays an even lower tolerance to mismatches [26] . These efforts have substantially broadened the scope of allele-specific applications to achieve various desired outcomes.
Replication stress-vulnerable sites in BRCA2-deficient cells
One previously unappreciated consequence of BRCA2 deficiency recently uncovered by others and us is the manifestation of S/G2 repair defects in later cell cycle stages, resulting in 53BP1 nuclear body formation in the subsequent G1 phase [14, 27] . What remains mysterious is the source of the replication stress. Understanding how 53BP1 nuclear bodies are formed is key to addressing this question.
53BP1 nuclear bodies were initially reported to mark common fragile sites (CFSs).
Treatment with low-dose aphidicolin (APH) is a commonly used method to specifically induce CFS instability [28] . It acts by perturbing DNA replication (polymerase α) without substantially affecting cell cycle progression, leading to breakage at the fragile sites in mitosis, termed CFS expression. The same treatment was found to massively stimulate formation of 53BP1 nuclear bodies at CFSs [29, 30] . By contrast, high doses of another replication inhibitor, hydroxyurea (HU), which does not display CFS selectivity, presumably due to a different a mode of action (in part, nucleotide pool depletion) [28] , fails to induce 53BP1 nuclear bodies [29] . Thus, in genetically unmodified cells, 53BP1 nuclear body formation appears to be associated with CFS expression.
To explore the sources of 53BP1 nuclear bodies arising from BRCA2 deficiency, we first benchmarked how control MCF10A cells respond to different replication stresses induced by APH and HU. BRCA2-proficient cells displayed ≥5-fold increase in these nuclear bodies with low doses of APH ( Fig. 2A) , consistent with a recent report [31] . 53BP1 nuclear bodies were somewhat increased with HU treatment [14] , but the level did not reach that seen with APH and this trend was not statistically significant ( Fig. 2B) . These results are consistent with previous findings [29] , showing that conditions that induce CFS expression (low-dose APH) lead to 53BP1 nuclear body formation, while HU exerts a minimal response at the dosage used.
Notably, upon BRCA2 disruption, the level of 53BP1 nuclear bodies was dramatically elevated not only by HU [14] , but also by APH (Fig. 2) . Interestingly, BRCA2-deficient cells displayed a level of spontaneous 53BP1 nuclear bodies that was comparable to that of BRCA2-proficient cells treated with low-dose APH ( Fig. 2A) , which provides an estimation of the level of spontaneous replication stress in these BRCA2-disrupted cells. Thus, BRCA2 suppresses replication stress that perturbs CFSs as well as other genomic sequences. This stress in turn leads to 53BP1 nuclear body formation when BRCA2 function is compromised.
We have previously shown that HU-induced replication stress is relieved by the HR function of BRCA2 [14] . Thus, HR disruption leads to fragility of genomic regions with distinct properties from those of CFSs upon HU. These properties are reminiscent of the recently discovered early replication fragile sites (ERFSs), which are characterized as regions bound by a set of DNA repair proteins, including the HR protein BRCA1, and prone to breakage in response to HU but not low-dose APH [32] . Since BRCA2-deficient cells display a high level of replication stress under both HU and low-dose APH treatment, multiple processes likely contribute to the replication stress seen in these cells. For example, BRCA2 prevents R-loop accumulation [33, 34] and maintains the integrity of telomeres [35] and G-quadruplex-forming sites [36] . Presumably these regions are more susceptible to replication stress and become fragile upon BRCA2 loss. It would be interesting for future studies to determine the full set of genomic regions that are particularly unstable upon BRCA2 deficiency and uncover the mechanism(s) of DNA fragility.
Link between 53BP1 nuclear bodies and p53 activation 53BP1 nuclear bodies form in G1, the cell cycle stage at which BRCA2-deficient cells arrest due to p53 activation [14] . To further characterize the link between 53BP1 nuclear bodies and p53 activation in BRCA2-deficient cells, we performed image analysis to determine whether the two proteins colocalize. Indeed, a substantial fraction (~60%) of 53BP1 nuclear bodies contained p53
and its active, phosphorylated form, p53-pS15 (Fig. 3A ,B,D,E). This colocalization occurred irrespective of BRCA2 status, although we observed a slight, but reproducible increase in the frequency of nuclear bodies with p53 signals in BRCA2-deficient cells (Fig. 3B,E) , possibly reflecting a positive feedback regulation of p53 levels in stressed conditions [37] . However, as a consequence of increased nuclear body abundance, BRCA2 deficiency led to a marked elevation of both p53-and p53-pS15-positive 53BP1 nuclear bodies in G1 phase (Fig. 3C,F) . Indeed, BRCA2 disruption is accompanied with an increase in spontaneous p53 levels in various systems [14, 38, 39] . Importantly, p53 disruption did not affect 53BP1 nuclear body formation (Fig. 3G) ,
suggesting that p53 functions downstream of the DNA lesions marked by 53BP1. Together, these results establish that 53BP1 nuclear bodies are spatially linked to p53 activation.
53BP1 nuclear bodies could activate p53 at multiple levels [8] , either directly through 53BP1-p53 interaction [40] or indirectly through the downstream DNA damage response. The underlying DNA lesions within the nuclear bodies may serve to activate signaling networks, including the p53 pathway. Indeed, 53BP1 nuclear bodies contain various components involved in the DNA damage response, including the master regulator ATM in its activated, phosphorylated form (pATM S1981) [30] , which directly stabilizes and activates p53 [41] .
Together, our results are consistent with a model that these nuclear compartments marked by 53BP1 serve as a signaling hub to recruit and activate p53. However, so far their relationship remains correlative and additional studies are needed to determine whether the relationship is causal and, if so, what are the mechanisms.
In addition to p53 activation, 53BP1 nuclear bodies may play other roles in BRCA2-deficient cells. For example, 53BP1 nuclear bodies sequester and shield the underlying sites of DNA damage [30] . Notably, removing 53BP1 dramatically enhances DNA break manifestation in the setting of CFS expression [30] . Thus, perturbing 53BP1 in BRCA2-deficient cells may similarly aggravate DNA break deprotection and thereby synergistically exacerbate genome instability phenotypes. This hypothesis, if found to be true, could potentially be exploited to develop novel synthetic lethal therapies for BRCA2-deficient cancers.
Functional interplay between SMARCAL1 and BRCA2
Having uncovered some unusual aspects of BRCA2 deficiency, our BRCA2 conditional systems also afford the opportunity to dissect the contribution of two pathways, HR and FP. To this end,
we developed multiple separation-of-function approaches to specifically perturb one pathway while keeping the other intact. These approaches converge on the conclusion that HR, rather than FP, plays the critical role in suppressing replication stress to support MCF10A cell survival [14] .
Replication fork reversal has emerged in multiple studies as a new aspect dictating the outcome of FP versus fork degradation, suggesting that forks that have not reversed will not be degraded [8, 42] . We therefore examined the impact of fork reversal on replication stress by depleting SMARCAL1, a DNA translocase known to exhibit fork reversion activity [43, 44, 45] .
In BRCA2-deficient cells, SMARCAL1 inactivation suppressed fork degradation (Fig. 4A) , consistent with recent observations [11, 13] and the model that fork reversal acts as a prerequisite for nascent strand degradation (Fig. 4B) . While FP was rescued, 53BP1 nuclear bodies were not significantly reduced in HU-treated BRCA2-deficient cells by SMARCAL1 depletion (Fig. 4C) .
Supporting these observations, inactivating ZRANB3, another DNA translocase that catalyzes fork reversal, also fails to abolish HU-induced chromosomal aberrations in BRCA2-deficient cells [12] . These results further corroborate our previous conclusions that FP is not critical for replication stress suppression.
These data recapitulate previous results that SMARCAL1-mediated fork reversal plays a critical role in promoting nascent strand degradation upon replication stress [11, 13] , adding to the expanding recent literature that implicates this process in the pathways involved in FP suppression [8] . FP restoration achieved by SMARCAL1 inactivation also represents an additional separation-of-function approach to study the contributions of the FP pathway in BRCA2-(and more generally HR-) deficient cells. Interestingly, SMARCAL1 depletion by itself led to a modest enhancement of HU-triggered 53BP1 nuclear body formation (Fig. 4C) . Given our previous findings that HR is critical to suppress replication stress [14] , the observed induction in 53BP1 nuclear bodies is reminiscent of a role of SMARCAL1 in HR, as has been reported in the fly system [49] . To determine the HR function of SMARCAL1 in MCF10A cells, we employed the DR-GFP reporter that is stably integrated as a single copy to assay HR activity [50, 51] (Fig. 4D) . Indeed, SMARCAL1 depletion led to a reduction in HR, although only to a moderate extent compared with that observed in cells depleted of the core HR component RAD51 [52] (Fig. 4D) . Thus, SMARCAL1
depletion by itself exerts a small increase in 53BP1 nuclear body formation that may be associated with its minor role in HR. We conclude that SMARCAL1 plays a minor role in suppressing replication stress when BRCA2 is present. In sum, our previous [14] and current results are all consistent with a model that HR plays a critical role in suppressing replication stress leading to 53BP1 nuclear bodies, whereas neither protection nor regression of replication forks substantially contributes to this process.
Concluding remarks
We have previously shown that BRCA2 suppresses DNA replication stress through HR [14] . We have now expanded on these findings, investigating three aspects of the replication stress triggered as a consequence of BRCA2 inactivation. First, we show that BRCA2-deficient cells are sensitized to two types of replication stress, those induced by HU and by low-dose APH.
Second, 53BP1 nuclear bodies spatially link replication stress to downstream p53 activation in G1 phase. Finally, disrupting fork reversal by SMARCAL1 depletion ameliorates the FP defect in BRCA2-deficient cells, but does not restrain 53BP1 nuclear body formation, further corroborating our previous model that FP plays a minor role in suppressing replication stress in MCF10A cells. transduction of self-deleting Cre recombinase, as previously described [14] .
Materials and methods

MCF10A Cell culture and chemicals
BRCA2
MCF10A cells were cultured in DME-HG/F-12 supplemented with 5% horse serum, 20 ng ml −1 epidermal growth factor, 0.5 mg ml −1 hydrocortisone, 10 µg ml −1 insulin, 100 ng ml
cholera toxin, and 1% penicillin-streptomycin.
Aphidicolin (0.1 µg ml -1 ; A4487, Sigma), hydroxyurea (4 mM; H8627, Sigma), IdU (50 µM; I7125, Sigma), CldU (50 µM; C6891, Sigma) were used for treatment as indicated.
Plasmid construction and gene targeting with CRISPR-Cas9
Hyg-targeting was performed as previously described [14] . Briefly, donor plasmid contains homology arms that are 700-900 bp in length. Wild-type Cas9-expression plasmid (Addgene plasmid # 41815) [53] (Fig. 1) or paired nickases (Cas9 H840A) [54, 55] (Fig. S1 ) and BRCA2 sgRNA(s), which were cloned into sgRNA backbone (Addgene plasmid # 41824) [53] , were used together with the donor plasmid. Transfection by electroporation (Gene Pulser II, Bio-Rad; 350 V, 1000 µF) was performed before selection for hygromycin (50 µg ml −1 ) resistance.
For genotyping PCR, trypsinized cell suspensions were mixed with PCR grade water and heated at 100 °C for 5 min before PCR analysis. Oligos 1 (forward) and 2 (reverse) were used to detect the Hyg-targeted allele. Oligos 1 (forward) and 3 (reverse) were used to detect the allele that had not been targeted by the Hyg cassette (i.e., the untargeted allele). Oligo 4 was used to 
RNA interference
Immunofluorescence and microscopy
Immunofluorescence was performed as described [14] . Briefly, cells were seeded on Nunc™ For APH/HU-induced 53BP1 nuclear body analyses (Fig. 2) , images were acquired under Axio2 microscope (Zeiss). For 53BP1-p53/p53-pS15 colocalization analyses (Fig.3 ), images
were acquired under DeltaVision Elite microscope (GE Healthcare). Deconvolution was carried out with z stacks acquired with 0.2 µm spacing using enhanced ratio method, and projected based on maximum intensity on a DeltaVision Image Restoration System (GE Healthcare). Image analysis was performed using high-content image-based cytometry methods as previously described [14, 56] , using FIJI (ImageJ).
Primary antibodies were used as follows: 53BP1 (1:1000; 612522, BD Biosciences), 53BP1 (1:1000; NB100-304, Novus), cyclin A (1:1000; sc-751, Santa Cruz Biotechnology), p53
(1:1000; Santa Cruz, sc-98), p53-pS15 (1:1000; CST, 9284). Secondary antibodies were used as follows: anti-mouse Alexa Fluor® 488, anti-rabbit Alexa Fluor® 488, anti-rabbit Alexa Fluor® 568, anti-mouse Alexa Fluor® 594, anti-rabbit Alexa Fluor® 594 (1:1000; Thermo Fisher Scientific).
DNA fiber assay
DNA fiber assay for FP analysis was performed as previously described [14] . Briefly, cells were pulse labeled with 50 µM IdU and 50 µM CldU, treated with 4 mM HU and lysed in lysis buffer 
HR assay
Cells were infected with an I-SceI-expressing lentivirus [14] . 48 h later, HR was quantified by measuring the fraction of GFP-positive cells using flow cytometry (Becton Dickinson FACScan) and FlowJo software. Schematic for generation of BRCA2 fl/-cells described in [14] . The Hyg cassette was designed to be specifically targeted to the BRCA2 WT, but not the fl allele. Unlike in Fig. 1 , the target allele (WT) contains the A nucleotide SNP, so an A allele-specific sgRNA was designed to achieve the 
